Coronary Artery Bypass Graft Surgery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report Download FREE Resources

Published: August 26, 2024 Report Code: GDME1799EPD-ST

Select Item

Coronary Artery Bypass Graft Surgery Pipeline Market Report Overview

Coronary artery bypass graft surgery devices are used in the surgery to improve blood flow to the obstructed coronary artery. Surgeons use these devices to treat people who have severe coronary heart disease.

The Coronary Artery Bypass Graft Surgery pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein the clinical trials are in progress, the regulatory paths followed by the trials, and the companies associated with the trials.

Key Territories ·       The United States

·       Europe

·       Israel

·       Canada
Key Regulatory Paths ·       PMA

·       CE

·       510(k)

·       MDL

·       NMPA
Leading Companies ·       Amt Medical BV

·       ArtiFex Medical GmbH

·       Axcelon Biopolymers Corp

·       CardioPolymers Inc

·       Cardious Inc
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Coronary Artery Bypass Graft Surgery Pipeline Market Segmentation by Territories

A few of the key territories with the Coronary Artery Bypass Graft Surgery pipeline market are Europe, the United States, Global, and Israel among others. As of August 2024, the US had the highest number of Coronary Artery Bypass Graft Surgery pipeline products.

Coronary Artery Bypass Graft Surgery Pipeline Market Analysis by Territories, 2024 (%)

Coronary Artery Bypass Graft Surgery Pipeline Market Analysis by Territories, 2024 (%)

Buy the Full Report for More Territory Insights into the Coronary Artery Bypass Graft Surgery Pipeline Market

Download a Free Report Sample

Coronary Artery Bypass Graft Surgery Pipeline Market Segmentation by Regulatory Paths

A few of the key regulatory paths in the Coronary Artery Bypass Graft Surgery pipeline products market are PMA, CE, NMPA, MDL, and 510(k). As of August 2024, PMA was the most followed pathway for pipeline products in the Coronary Artery Bypass Graft Surgery market.

Coronary Artery Bypass Graft Surgery Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Coronary Artery Bypass Graft Surgery Pipeline Market Analysis by Regulatory Paths, 2024 (%)

Buy the Full Report for More Regulatory Path Insights into the Coronary Artery Bypass Graft Surgery Pipeline Market

Download a Free Report Sample

Coronary Artery Bypass Graft Surgery Pipeline Market – Competitive Landscape

A few of the key companies associated with the Coronary Artery Bypass Graft Surgery pipeline market are Amt Medical BV, Artifex Medical GmbH, Axcelon Biopolymers Corp, CardioPolymers Inc., and Cardious Inc. among others.

AMT Medical BV: It is a provider of pre-clinical stage medical devices to develop heart bypass surgery. The company’s technology platform ELANA specializes in designing coronary bypass technology to reduce bypass complications and shorten patient recovery. Its product offerings include surgical tools and healthcare devices. The company’s service offerings include ELANA heart bypass solution, ELANA brain solution, and research and development services. It is headquartered in Ede, Gelderland, The Netherlands.

Coronary Artery Bypass Graft Surgery Pipeline Market Analysis by Companies, 2024
Coronary Artery Bypass Graft Surgery Pipeline Market Analysis by Companies, 2024Buy the Full Report for More Company Insights into the Coronary Artery Bypass Graft Surgery Pipeline Market
Download a Free Report Sample

Segments Covered in the Report

Coronary Artery Bypass Graft Surgery Pipeline Market Territories Outlook (2024)

  • The United States
  • Europe
  • Global
  • Israel

Coronary Artery Bypass Graft Surgery Pipeline Market Regulatory Paths Outlook (2024)

  • PMA
  • CE
  • 510(k)
  • MDL
  • NMPA

Scope

This report provides:

  • Extensive coverage of the coronary artery bypass graft surgery devices under development.

  • An exhaustive list of major pipeline products and their details, including product description, licensing and collaboration details, and other developmental activities.

  • Reviews of major players involved in the development of coronary artery bypass graft surgery and lists all their pipeline projects.

  • Coverage of pipeline products based on various stages of development ranging from early development to approved/issued stage.

  • Key clinical trial data of ongoing clinical trials specific to pipeline products.

  • Recent developments in the segment/industry.

Reasons to Buy

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies.

  • Identify emerging players with potentially strong product portfolios and create effective counter strategies to gain a competitive advantage.

  • Identify and understand important and diverse types of coronary artery bypass graft surgery under development.

  • Develop market-entry and market-expansion strategies.

  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline.

  • Carry out an in-depth analysis of the product’s current stage of development, territory, and estimated launch date.

Amt Medical BV
ArtiFex Medical GmbH
Axcelon Biopolymers Corp
CardioPolymers Inc
Cardious Inc
Coromedic Ltd.
Cytograft Tissue Engineering Inc (Inactive)
enVVeno Medical Corp
Graft-Loc Inc.
H. Lee Moffitt Cancer Center & Research Institute Inc
Haimai Medical Technology Co Ltd
iiTech BV
McGill University
Medical 21 Inc
Myocardial Assist Systems and Technology LLC
Neograft Technologies Inc
Nordicus Partners Corp
PetVivo Holdings Inc
Prekubator TTO
RegenMedTX LLC
SeamVad Ltd.
Surg Solutions SL
University College London
University of Arizona
University of California Davis
University of California Los Angeles
Xeltis AG

Table of Contents

  • 1 Table of Contents

    • 1.1 List of Tables

    • 1.2 List of Figures

  • 2 Introduction

    • 2.1 Coronary Artery Bypass Graft Surgery Overview

  • 3 Products under Development

    • 3.1 Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development

    • 3.2 Coronary Artery Bypass Graft Surgery – Pipeline Products by Territory

    • 3.3 Coronary Artery Bypass Graft Surgery – Pipeline Products by Regulatory Path

    • 3.4 Coronary Artery Bypass Graft Surgery – Pipeline Products by Estimated Approval Date

    • 3.5 Coronary Artery Bypass Graft Surgery – Ongoing Clinical Trials

  • 4 Coronary Artery Bypass Graft Surgery – Pipeline Products under Development by Companies

    • 4.1 Coronary Artery Bypass Graft Surgery Companies – Pipeline Products by Stage of Development

    • 4.2 Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development

  • 5 Coronary Artery Bypass Graft Surgery Companies and Product Overview

    • 5.1 Amt Medical BV Company Overview

      • 5.1.1 Amt Medical BV Pipeline Products & Ongoing Clinical Trials Overview

    • 5.2 ArtiFex Medical GmbH Company Overview

      • 5.2.1 ArtiFex Medical GmbH Pipeline Products & Ongoing Clinical Trials Overview

    • 5.3 Axcelon Biopolymers Corp Company Overview

      • 5.3.1 Axcelon Biopolymers Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.4 CardioPolymers Inc Company Overview

      • 5.4.1 CardioPolymers Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.5 Cardious Inc Company Overview

      • 5.5.1 Cardious Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.6 Coromedic Ltd. Company Overview

      • 5.6.1 Coromedic Ltd. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.7 Cytograft Tissue Engineering Inc (Inactive) Company Overview

      • 5.7.1 Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview

    • 5.8 enVVeno Medical Corp Company Overview

      • 5.8.1 enVVeno Medical Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.9 Graft-Loc Inc. Company Overview

      • 5.9.1 Graft-Loc Inc. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.10 H. Lee Moffitt Cancer Center & Research Institute Inc Company Overview

      • 5.10.1 H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.11 Haimai Medical Technology Co Ltd Company Overview

      • 5.11.1 Haimai Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview

    • 5.12 iiTech BV Company Overview

      • 5.12.1 iiTech BV Pipeline Products & Ongoing Clinical Trials Overview

    • 5.13 McGill University Company Overview

      • 5.13.1 McGill University Pipeline Products & Ongoing Clinical Trials Overview

    • 5.14 Medical 21 Inc Company Overview

      • 5.14.1 Medical 21 Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.15 Myocardial Assist Systems and Technology LLC Company Overview

      • 5.15.1 Myocardial Assist Systems and Technology LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.16 Neograft Technologies Inc Company Overview

      • 5.16.1 Neograft Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.17 Nordicus Partners Corp Company Overview

      • 5.17.1 Nordicus Partners Corp Pipeline Products & Ongoing Clinical Trials Overview

    • 5.18 PetVivo Holdings Inc Company Overview

      • 5.18.1 PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview

    • 5.19 Prekubator TTO Company Overview

      • 5.19.1 Prekubator TTO Pipeline Products & Ongoing Clinical Trials Overview

    • 5.20 RegenMedTX LLC Company Overview

      • 5.20.1 RegenMedTX LLC Pipeline Products & Ongoing Clinical Trials Overview

    • 5.21 SeamVad Ltd. Company Overview

      • 5.21.1 SeamVad Ltd. Pipeline Products & Ongoing Clinical Trials Overview

    • 5.22 Surg Solutions SL Company Overview

      • 5.22.1 Surg Solutions SL Pipeline Products & Ongoing Clinical Trials Overview

    • 5.23 University College London Company Overview

      • 5.23.1 University College London Pipeline Products & Ongoing Clinical Trials Overview

    • 5.24 University of Arizona Company Overview

      • 5.24.1 University of Arizona Pipeline Products & Ongoing Clinical Trials Overview

    • 5.25 University of California Davis Company Overview

      • 5.25.1 University of California Davis Pipeline Products & Ongoing Clinical Trials Overview

    • 5.26 University of California Los Angeles Company Overview

      • 5.26.1 University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview

    • 5.27 Xeltis AG Company Overview

      • 5.27.1 Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview

  • 6 Coronary Artery Bypass Graft Surgery- Recent Developments

    • 6.1 Jun 13, 2024: Medtronic Confirms Global Layoffs

    • 6.2 Apr 12, 2024: Biotech Firms Genentech, Sanofi Laying off Hundreds at South San Francisco

    • 6.3 Mar 12, 2024: Medtronic To Present At Barclays Global Healthcare Conference

    • 6.4 Feb 28, 2024: Boston Scientific Raises $2.2B to Support Purchase of California Medical Device Company

    • 6.5 Feb 28, 2024: Providence St. Patrick Hospital Offers Advanced Life-Support for Patients in Critical Care

    • 6.6 Feb 23, 2024: Medical Tech Leader, Boston Scientific (BSX), Announces Notes Offering

    • 6.7 Feb 15, 2024: Stephen Agostini Named UCLA’s Vice Chancellor and Chief Financial Officer

    • 6.8 Jan 16, 2024: New Initiative Focuses on Oral Health Clinicians in Prevention and Early Detection of Heart Disease

    • 6.9 Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results

    • 6.10 Nov 22, 2023: United Imaging Intelligence To Unveil Cutting-Edge AI Technology at RSNA

  • 7 Appendix

    • 7.1 Methodology

    • 7.2 About GlobalData

    • 7.3 Contact Us

    • 7.4 Disclaimer

Table

Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development 9

Coronary Artery Bypass Graft Surgery – Pipeline Products by Territory 10

Coronary Artery Bypass Graft Surgery – Pipeline Products by Regulatory Path 11

Coronary Artery Bypass Graft Surgery – Pipeline Products by Estimated Approval Date 12

Coronary Artery Bypass Graft Surgery – Ongoing Clinical Trials 13

Coronary Artery Bypass Graft Surgery Companies – Pipeline Products by Stage of Development 14

Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development 16

Amt Medical BV Pipeline Products & Ongoing Clinical Trials Overview 17

ELANA Heart Bypass System – Product Status 17

ELANA Heart Bypass System – Product Description 17

ArtiFex Medical GmbH Pipeline Products & Ongoing Clinical Trials Overview 18

ArtiFex Vascular Graft – Product Status 18

ArtiFex Vascular Graft – Product Description 18

Axcelon Biopolymers Corp Pipeline Products & Ongoing Clinical Trials Overview 19

BNC – PVA Based Vascular Graft – Product Status 19

BNC – PVA Based Vascular Graft – Product Description 19

CardioPolymers Inc Pipeline Products & Ongoing Clinical Trials Overview 20

Plexisyl-AF – Product Status 20

Plexisyl-AF – Product Description 20

Cardious Inc Pipeline Products & Ongoing Clinical Trials Overview 21

AvA Aortic Valve Bypass Graft System – Product Status 21

AvA Aortic Valve Bypass Graft System – Product Description 21

Coromedic Ltd. Pipeline Products & Ongoing Clinical Trials Overview 22

Distal Anastomosis Device – Product Status 22

Distal Anastomosis Device – Product Description 22

Proximal Anastomosis Device – Product Status 23

Proximal Anastomosis Device – Product Description 23

Cytograft Tissue Engineering Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 24

LifeLine TEBV – CABG – Product Status 24

LifeLine TEBV – CABG – Product Description 24

enVVeno Medical Corp Pipeline Products & Ongoing Clinical Trials Overview 25

CoreoGraft – Product Status 25

CoreoGraft – Product Description 25

Graft-Loc Inc. Pipeline Products & Ongoing Clinical Trials Overview 26

Graft-Loc Device – Product Status 26

Graft-Loc Device – Product Description 26

H. Lee Moffitt Cancer Center & Research Institute Inc Pipeline Products & Ongoing Clinical Trials Overview 27

Vascular Stent – Product Status 27

Vascular Stent – Product Description 27

Haimai Medical Technology Co Ltd Pipeline Products & Ongoing Clinical Trials Overview 28

Tissue Engineered Blood Vessel – Coronary Heart Disease Bypass Surgery – Product Status 28

Tissue Engineered Blood Vessel – Coronary Heart Disease Bypass Surgery – Product Description 28

iiTech BV Pipeline Products & Ongoing Clinical Trials Overview 29

S² Distal Anastomotic System – Product Status 29

S² Distal Anastomotic System – Product Description 29

S2 Proximal Anastomotic System – Product Status 30

S2 Proximal Anastomotic System – Product Description 30

McGill University Pipeline Products & Ongoing Clinical Trials Overview 31

Transcatheter Aorta Pulmonary Shunt – Product Status 31

Transcatheter Aorta Pulmonary Shunt – Product Description 31

Medical 21 Inc Pipeline Products & Ongoing Clinical Trials Overview 32

Maverics Graft – Product Status 32

Maverics Graft – Product Description 32

Myocardial Assist Systems and Technology LLC Pipeline Products & Ongoing Clinical Trials Overview 33

Sutureless Anastomotic Graft Connection Device – Product Status 33

Sutureless Anastomotic Graft Connection Device – Product Description 33

Neograft Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 34

Neovaso – Product Status 34

Neovaso – Product Description 34

Nordicus Partners Corp Pipeline Products & Ongoing Clinical Trials Overview 35

CardioPass – Product Status 35

CardioPass – Product Description 35

PetVivo Holdings Inc Pipeline Products & Ongoing Clinical Trials Overview 36

Coronary Artery Bypass Graft – Product Status 36

Coronary Artery Bypass Graft – Product Description 36

Prekubator TTO Pipeline Products & Ongoing Clinical Trials Overview 37

Snapcon – Product Status 37

Snapcon – Product Description 37

RegenMedTX LLC Pipeline Products & Ongoing Clinical Trials Overview 38

Neo-Vessel Replacement – Coronary Artery Bypass – Product Status 38

Neo-Vessel Replacement – Coronary Artery Bypass – Product Description 38

SeamVad Ltd. Pipeline Products & Ongoing Clinical Trials Overview 39

MySide – Product Status 39

MySide – Product Description 39

Surg Solutions SL Pipeline Products & Ongoing Clinical Trials Overview 40

VessConnect – Product Status 40

VessConnect – Product Description 40

University College London Pipeline Products & Ongoing Clinical Trials Overview 41

Small Diameter Conduit – Product Status 41

Small Diameter Conduit – Product Description 41

University of Arizona Pipeline Products & Ongoing Clinical Trials Overview 42

Vascular Anastomosis Device – Product Status 42

Vascular Anastomosis Device – Product Description 42

University of California Davis Pipeline Products & Ongoing Clinical Trials Overview 43

Vascular Anastomosis Device – Product Status 43

Vascular Anastomosis Device – Product Description 43

University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview 44

Sutureless Anastomosis Device – Product Status 44

Sutureless Anastomosis Device – Product Description 44

Xeltis AG Pipeline Products & Ongoing Clinical Trials Overview 45

Xeltis Coronary Artery Bypass Graft – Product Status 45

Xeltis Coronary Artery Bypass Graft – Product Description 45

Xeltis AG – Ongoing Clinical Trials Overview 46

Xeltis Coronary Artery Bypass Graft – Prospective, Non-randomized, First in Human (FIH) Clinical Study to Assess the Feasibility of the Novel Xeltis Coronary Artery Bypass Graft (XABG) 47

Glossary 54

Figures

Coronary Artery Bypass Graft Surgery – Pipeline Products by Stage of Development 9

Coronary Artery Bypass Graft Surgery – Pipeline Products by Territory 10

Coronary Artery Bypass Graft Surgery – Pipeline Products by Regulatory Path 11

Coronary Artery Bypass Graft Surgery – Pipeline Products by Estimated Approval Date 12

Coronary Artery Bypass Graft Surgery – Ongoing Clinical Trials 13

Frequently asked questions

Coronary Artery Bypass Graft Surgery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Coronary Artery Bypass Graft Surgery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Coronary Artery Bypass Graft Surgery reports
Medical Devices
New
Global M&A Deals in H1 2026 - Top Themes by…
$495 | August 2026
Medical Devices
New
Medical Devices M&A Deals H1 2026 - Top Themes: Strategic…
$495 | July 2026
Medical Devices
New
AI-designed Materials: Market Trends and Innovations
$995 | July 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Coronary Artery Bypass Graft Surgery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies in real time.

  • Access a live Coronary Artery Bypass Graft Surgery Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more